Announcement

June 18

CEO Stefan Tell has decided to look for new opportunities outside CarpoNovum. 

We would like to thank Stefan for his contribution. 

As a consequence, Anders Grönberg has been reinstated as CEO of CarpoNovum AB, effective June 17th, 2020. 

C-REX clinical study in Stockholm delayed due to Covid-19

April 28

Due to unprecedented situation in Stockholm region caused by the Covid-19 outbreak, the C-REX clinical study has been delayed until further notice. 

The scope of the study and the intention to enroll two hundred patients undergoing colon and rectum resections in Stockholm region remains unchanged. 

C-REX CE-marking renewed until 2024

CarpoNovum has received MDD certificate to maintain its CE-marking of C-REX devices, valid until May 26, 2024.

Stefan Tell takes over as new CEO of CarpoNovum

Stefan Tell, MBA takes over as the new CEO of CarpoNovum from January 1, 2020. Former CEO Anders Grönberg moves into the new role as chief medical and operations officer. 

New clinical study in Shanghai with C-REX® LapAid®

June 18

After successful clinical study in Xiamen, CarpoNovum has started a new clinical study in Shanghai. For more information, please visit clinicaltrials.gov (NCT03404934). 

Extraordinary Shareholders' Meeting

December 4

Extraordinary Shareholders' meeting was held on December 4, 2018. At the meeting it was decided that Board should consist of four members. 

​

The board was constituted as follows: Chairman Thomas Enckell, Board members Anders Grönberg, Henrik Thorlacius and Jonas Gulliksson.

Issue of Shares No 14

The ongoing issue of shares, No 14 is prolonged 2 weeks, until December 21,  2018.

Annual General Meeting 2018

The 2018 CarpoNovum Shareholders’ annual Meeting took place on May 24th, 2018 in Lund. Regardless of the number of shares they hold, all shareholders are invited to take part in the Shareholders’ Meeting and talk with CarpoNovum’s CEO and Board.

​

At the meeting, Jonas Gulliksson was honored for his efforts as Chairman of the Board.

​

CEO presented notable events since last year’s meeting. Discussion was held about the ongoing clinical study Shanghai.

​

The AGM also authorized the Board to decide on the issue on one or more occasions until the next AGM.

​

It was decided that, until the end of the next AGM, Anders Grönberg, Bengt Sjöholm, Jonas Gulliksson, Harald Castler, Anders Forkman, Denis Viet-Jacobsen and Lars Peter Harbing will be elected as regular members.